Aktieanalys

Össur: FY'23 guidance to the soft side - ABG

ABG Sundal Collier Publicerad: 31 Jan 2023 09:02

Solid Q4 top-line, but margins fail to reach expectations
FY'23 guidance indicates a soft margin expansion outlook
We expect the share to trade slightly negative today

Q4 saw a strong rebound within bionics sales

Solid Q4 on the top line, driven by strong performance within the prosthetics subsegment, bionics, which accounted for 25% of prosthetic component sales vs. 23% in Q4'21. The increase was mainly driven by the power knee sales. However, the margins in Q4 did not reach company-collected consensus expectations, with the EBITDA margin reaching 18% (cons. 20%), indicating a slower-than-expected margin uptake, as the company still works to mitigate the increased cost base, with price increases.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2023/1/ossur---fy23-guidance-to-the-soft-side/

Nyheter om Embla Medical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!